RxDoctor Payments Data

Deepti Zutshi, MD

Neurology · Detroit, MINPI 1568621696

Payments from drug & device makers

$15,469in general payments, 2019–2025

Across 57 payments — averaging $271.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$7K
  • Aucta Pharmaceuticals, Inc.$6K
  • UCB, Inc.$689
  • SK Life Science, Inc.$460
  • Jazz Pharmaceuticals Inc.$432
  • Neurelis, Inc.$300
  • plus $414 from 6 others
$20,000in research payments, 2019–2025

Across 4 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB, Inc.$20K

What the payments were for

  • Consulting fees$6,00070%
  • Food & beverage$2,62330%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,469 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$37,953
Medicare patients
169
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam104$197,085
FycompaPerampanel24$21,873
Lacosamide140$20,627
KeppraLevetiracetam11$18,296
AptiomEslicarbazepine Acetate13$16,333
Clobazam73$9,688
Levetiracetam112$5,403
Carbamazepine ErCarbamazepine16$1,900
Lamotrigine61$1,192
Zonisamide52$1,146
Divalproex Sodium22$975
Gabapentin32$873
AmantadineAmantadine Hcl12$800
Topiramate19$575
Levetiracetam ErLevetiracetam14$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$689$197,085104 claims
Eisai Inc.Fycompa$7,155$21,87324 claims
Sunovion Pharmaceuticals Inc.Aptiom$18$16,33313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →